Filing Details

Accession Number:
0000905718-14-000703
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-29 19:31:27
Reporting Period:
2014-10-27
Filing Date:
2014-10-29
Accepted Time:
2014-10-29 19:31:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1359931 Proteon Therapeutics Inc PRTO Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1397144 Llp Abingworth 38 Jermyn Street
London X0 SW1Y 6DN
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-10-27 950,000 $10.00 950,000 No 4 P Indirect See Note
Common Stock Acquisiton 2014-10-27 1,067,872 $0.00 2,017,872 No 4 C Indirect See Note
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Note
No 4 C Indirect See Note
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series D Convertible Preferred Stock Disposition 2014-10-27 16,044,081 $0.00 1,010,969 $0.00
Series D Convertible Preferred Stock Option (Right to Purchase) Disposition 2014-10-27 12,835,264 $0.00 808,775 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 J Indirect
Footnotes
  1. These shares were purchased in connection with the Issuer's initial public offering of Common Stock.
  2. The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  3. Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 56,903 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation.
  4. Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.
  5. Abingworth had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (3) above.